MedTrace Logo

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

NCT03642561 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-07-28

No results posted yet for this study

Summary

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Conditions

Interventions

DEVICE

radiotherapy ablation

We using Cool Tip system or RITA system to perform RFA

DEVICE

transarterial chemoembolization(TACE)

TACE treatment is a first line treatment for BCLC stage B HCC

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Zhenggang Ren, doctor · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-03
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03642561 on ClinicalTrials.gov